Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Moderna argued that Section 1498 applies such that U.S. taxpayers should assume liability for its infringement of Genevant's and Arbutus' patents for sales made under one of its government contracts

  80% confidence

• Arbutus scientists changed the drug development landscape when they invented LNP delivery technology, enabling nucleic acids including mRNA to be used for medicines and opening a new world of possibilities

  80% confidence

• If the $1.3 billion payment is realized, this settlement will be the largest disclosed patent settlement paid in the pharmaceutical industry and the second largest in any industry

  80% confidence

• This settlement allows us to put this lengthy dispute behind us and remain focused on our mission to leverage our world-class nucleic acid delivery systems to bring innovative medicines to people who need them

  80% confidence

• The COVID-19 vaccines would never have made it to the world without the seminal work of Ian MacLachlan, Ed Yaworski, Lloyd Jeffs, Kieu Lam, Lorne Palmer, and Cory Giesbrecht

  80% confidence

• Moderna has acknowledged the contribution of Arbutus scientists and this is a transformative outcome for Arbutus

  80% confidence

• It is enormously gratifying for the Genevant team to be recognized for their pivotal contribution to restoring normalcy around the world in the face of a once-in-a-lifetime pandemic

  80% confidence